PYXS

1.8107.74%
BN

Balu N. Balasubramanian

Interim Chief Technology Officer

Dr. Balu N. Balasubramanian PhD, ACSF, serves as Interim Chief Technology Officer of Pyxis Oncology, Inc. since 2022. He served as Managing Director of Bristol-Myers Squibb-Biocon Research Center. Dr. Balasubramanian leads the Pharma Innovation Sourcing Center. Dr. Balasubramanian has over 25 years of scientific and management experience in drug discovery and early clinical development. He serves as Board Observer at Outlook Therapeutics, Inc. (formerly known as Oncobiologics, Inc.) He served as a Member of scientific Advisory Board at Cadila Healthcare Limited since December 15, 2011.

Positions